Probability-adjusted forecasts based on clinical trial phase, incorporating regulatory approval likelihoods
Assessing patent portfolios, exclusivity periods, data protection and IP monetisation potential
Approval pathways, reimbursement and payer decisions, pricing and adoption curves as drivers of commercial value
Valuation for mergers, acquisitions, licensing deals, milestone and royalty structures, and strategic partnerships
Measuring contributions to healthcare outcomes and sustainability goals
Models built to satisfy institutional investors and regulators
Clear articulation of assumptions, probabilities and value drivers
Aligned with how life sciences investors assess risk and opportunity